Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
Patient infected with West Nile virus in the Arnhem region In the past week, six human infections with the West Nile virus have been detected in the Netherlands.
First West Nile virus patient in the Netherlands A male patient has been diagnosed with the West Nile virus last week. The man has not been abroad recently. He may have contracted the virus in the region of Utrecht due to a mosquito bite.
Can you solve a medical mystery? During World Antibiotic Awareness Week 2019, RIVM has set up an escape room in one of busiest shopping malls in the Netherlands.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.